These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 36594666)

  • 1. The comparison of biodistribution of glutathione PEGylated nanoliposomal doxorubicin formulations prepared by pre-insertion and post-insertion methods for brain delivery in normal mice.
    Mehrabian A; Dadpour S; Mashreghi M; Zarqi J; Askarizadeh A; Badiee A; Arabi L; Moosavian SA; Jaafari MR
    IET Nanobiotechnol; 2023 Apr; 17(2):112-124. PubMed ID: 36594666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preparation, characterization, and biodistribution of glutathione PEGylated nanoliposomal doxorubicin for brain drug delivery with a post-insertion approach.
    Mehrabian A; Vakili-Ghartavol R; Mashreghi M; Shokooh Saremi S; Badiee A; Arabi L; Alavizadeh SH; Moosavian SA; Jaafari MR
    Iran J Basic Med Sci; 2022 Mar; 25(3):302-312. PubMed ID: 35656188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics, brain delivery, and efficacy in brain tumor-bearing mice of glutathione pegylated liposomal doxorubicin (2B3-101).
    Gaillard PJ; Appeldoorn CC; Dorland R; van Kregten J; Manca F; Vugts DJ; Windhorst B; van Dongen GA; de Vries HE; Maussang D; van Tellingen O
    PLoS One; 2014; 9(1):e82331. PubMed ID: 24416140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced doxorubicin delivery to the brain administered through glutathione PEGylated liposomal doxorubicin (2B3-101) as compared with generic Caelyx,(®)/Doxil(®)--a cerebral open flow microperfusion pilot study.
    Birngruber T; Raml R; Gladdines W; Gatschelhofer C; Gander E; Ghosh A; Kroath T; Gaillard PJ; Pieber TR; Sinner F
    J Pharm Sci; 2014 Jul; 103(7):1945-1948. PubMed ID: 24801480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preparation and characterization of PEGylated liposomal Doxorubicin targeted with leptin-derived peptide and evaluation of their anti-tumor effects, in vitro and in vivo in mice bearing C26 colon carcinoma.
    Shahraki N; Mehrabian A; Amiri-Darban S; Moosavian SA; Jaafari MR
    Colloids Surf B Biointerfaces; 2021 Apr; 200():111589. PubMed ID: 33545570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study of FA12 peptide-modified PEGylated liposomal doxorubicin (PLD) as an effective ligand to target Muc1 in mice bearing C26 colon carcinoma: in silico, in vitro, and in vivo study.
    Biabangard A; Asoodeh A; Jaafari MR; Mashreghi M
    Expert Opin Drug Deliv; 2022 Dec; 19(12):1710-1724. PubMed ID: 36373415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced glutathione PEGylated liposomal brain delivery of an anti-amyloid single domain antibody fragment in a mouse model for Alzheimer's disease.
    Rotman M; Welling MM; Bunschoten A; de Backer ME; Rip J; Nabuurs RJ; Gaillard PJ; van Buchem MA; van der Maarel SM; van der Weerd L
    J Control Release; 2015 Apr; 203():40-50. PubMed ID: 25668771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of glutathione conjugation on the transcellular transport process of PEGylated liposomes across the blood brain barrier.
    Reginald-Opara JN; Tang M; Svirskis D; Chamley L; Wu Z
    Int J Pharm; 2022 Oct; 626():122152. PubMed ID: 36055442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer.
    Charrois GJ; Allen TM
    Biochim Biophys Acta; 2004 May; 1663(1-2):167-77. PubMed ID: 15157619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of size in PEGylated liposomal doxorubicin biodistribution and anti-tumour activity.
    Dadpour S; Mehrabian A; Arabsalmani M; Mirhadi E; Askarizadeh A; Mashreghi M; Jaafari MR
    IET Nanobiotechnol; 2022 Sep; 16(7-8):259-272. PubMed ID: 35983586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Comparison of Biodistribution, Efficacy and Toxicity of Two PEGylated Liposomal Doxorubicin Formulations in Mice Bearing C-26 Colon Carcinoma: a Preclinical Study.
    Razavi-Azarkhiavi K; Jafarian AH; Abnous K; Razavi BM; Shirani K; Zeinali M; Jaafari MR; Karimi G
    Drug Res (Stuttg); 2016 Jun; 66(6):330-6. PubMed ID: 27022719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting brain cells with glutathione-modulated nanoliposomes: in vitro and in vivo study.
    Salem HF; Ahmed SM; Hassaballah AE; Omar MM
    Drug Des Devel Ther; 2015; 9():3705-27. PubMed ID: 26229435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tat peptide and hexadecylphosphocholine introduction into pegylated liposomal doxorubicin: An in vitro and in vivo study on drug cellular delivery, release, biodistribution and antitumor activity.
    Teymouri M; Badiee A; Golmohammadzadeh S; Sadri K; Akhtari J; Mellat M; Nikpoor AR; Jaafari MR
    Int J Pharm; 2016 Sep; 511(1):236-244. PubMed ID: 27363937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative study of folate receptor-targeted doxorubicin delivery systems: dosing regimens and therapeutic index.
    Scomparin A; Salmaso S; Eldar-Boock A; Ben-Shushan D; Ferber S; Tiram G; Shmeeda H; Landa-Rouben N; Leor J; Caliceti P; Gabizon A; Satchi-Fainaro R
    J Control Release; 2015 Jun; 208():106-20. PubMed ID: 25869964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?
    Mamidi RN; Weng S; Stellar S; Wang C; Yu N; Huang T; Tonelli AP; Kelley MF; Angiuoli A; Fung MC
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1173-84. PubMed ID: 20661737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted brain delivery of methotrexate by glutathione PEGylated liposomes: How can the formulation make a difference?
    Hu Y; Gaillard PJ; de Lange ECM; Hammarlund-Udenaes M
    Eur J Pharm Biopharm; 2019 Jun; 139():197-204. PubMed ID: 30951819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of an apolipoprotein E mimetic peptide-lipid conjugate for efficient brain delivery of liposomes.
    Kato N; Yamada S; Suzuki R; Iida Y; Matsumoto M; Fumoto S; Arima H; Mukai H; Kawakami S
    Drug Deliv; 2023 Dec; 30(1):2173333. PubMed ID: 36718920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy?
    Cui J; Li C; Guo W; Li Y; Wang C; Zhang L; Zhang L; Hao Y; Wang Y
    J Control Release; 2007 Apr; 118(2):204-15. PubMed ID: 17239468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving anti-tumour efficacy of PEGylated liposomal doxorubicin by dual targeting of tumour cells and tumour endothelial cells using anti-p32 CGKRK peptide.
    Mashreghi M; Faal Maleki M; Karimi M; Kalalinia F; Badiee A; Jaafari MR
    J Drug Target; 2021 Jul; 29(6):617-630. PubMed ID: 33393376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies.
    Gabizon A; Shmeeda H; Barenholz Y
    Clin Pharmacokinet; 2003; 42(5):419-36. PubMed ID: 12739982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.